ClinicalTrials.gg
CompletedNCT05229536Updated Feb 25, 2022

Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

A Phase 2 interventional study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine and Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Meningitis, Meningococcal, sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 3 Months to 35 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Dec 2018, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
3 Months to 35 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.

Enrollment
12th of 19
720 · median 840
Started
2018
with 1 other
Phase 2
2 of 19
1 open now
Registered
7th of 19
by date
Lead sponsor
4 of 19
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 2, and was the 7th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 3 Months to 35 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Meningitis, Meningococcal with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 35 years.

03

Conditions studied

  • Meningitis, Meningococcal
04

Who can participate

Ages eligible
3 Months to 35 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People aged 3-35 months;
  • Subject who has not been vaccinated with meningococcal group A and C conjugate vaccine, meningococcal group A polysaccharide vaccine and meningococcal group A and C and haemophilus b conjugate vaccine at the aged of 3-11 months, and who have't given boost immunity above 1 year old, and they all meet the physical examination requirements of the project;
  • Infants aged 3-11 months should be full-term (37-42 weeks of gestation) and their birth weight should meet the requirements (2500g ≤ body weight ≤ 4000g);
  • The guardian signs the form;
  • The guardian and his family agree to comply with the requirements of the clinical trial protocol;
  • Subject who had no history of other within 14 days before vaccination and no history of other inactivated vaccines within 7 days;
  • Axillary body temperature ≤ 37.0 ℃.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reactions requiring medical intervention (such as swelling of mouth and throat, dyspnea, hypotension or shock);
  • Have a history of allergy to the vaccine or vaccine ingredients (especially those allergic to tetanus toxoid), or have a history of other serious adverse reactions to the vaccine;
  • A clearly diagnosed history of thrombocytopenia or other coagulation disorders that may cause to intramuscular injection;
  • Abnormal production process, asphyxia rescue history, or congenital malformation, developmental disorder or serious chronic disease;
  • Has serious cardiovascular, liver and kidney diseases or congenital abnormalities and infection;
  • Suffer from encephalopathy, uncontrolled epilepsy, convulsion and other progressive nervous system diseases;
  • Acute disease, severe chronic disease, acute attack of chronic disease and fever (axillary body temperature ≥ 38.0 ℃) in the past 3 days;
  • Plan to participate or be participating in any other drug clinical research;
  • The interval between the first dose of test vaccine and meningococcal group A polysaccharide vaccine is less than 28 days;
  • According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
720 participants (actual)

Study arms

  • Experimental
    High dose Group

    Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 40μg/dose

    Biological: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

  • Experimental
    Low dose Group

    Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine, 20μg/dose

    Biological: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

Interventions

  • BiologicalMeningococcal ACYW135 Polysaccharide Conjugate Vaccine

    Group 1: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.

  • BiologicalMeningococcal ACYW135 Polysaccharide Conjugate Vaccine

    Group 2: 3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugate.

06

What researchers measure

Primary outcomes

  1. Immunogenicity study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine as assessed by positive conversion rate

    Time frame: 30 day after each vaccination

  2. Safety study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine as assessed by the occurrence of adverse events

    Evaluate the incidence of adverse reactions for Meningococcal ACYW135 Polysaccharide Conjugate Vaccine

    Time frame: 30 day after each vaccination

07

Study locations

1 site
  • Rongan Center for Disease Control and Prevention
    Liuzhou, Guangxi 530028, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Nov 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Feb 8, 2022
StartActual
Dec 21, 2018
Primary completionActual
Nov 21, 2019
CompletionActual
Nov 21, 2019
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05229536
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Dec 21, 2018
Primary completion
Nov 21, 2019
Completion
Nov 21, 2019
Last update
Feb 25, 2022

Study contacts

Lin Du
study chair · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion